Cryptococcosis is a serious threat to the immunocompromised patient. Current approaches to therapy present numerous problems for the clinician. Available antibiotics frequently have a high toxicity, and failure rates can be high, particularly in the patient with acquired immunodeficiency syndrome. One possible alternative or adjunct to chemotherapy is the use of passive immunization with immune globulin. Passive immunization with monoclonal antibodies (MAbs) has proven successful in animal models of infection by several encapsulated bacteria, including Haemophilus influenzae type b (6), Streptococcus pneumoniae (1) , group B Streptococcus spp. (24) , and Neisseria meningitidis (2) .
The use of antibody for passive immunization against experimental cryptococcosis has been an elusive goal. Gadebusch (5) and Graybill et al. (10) reported that mice could be protected against experimental cryptococcosis by passive immunization with rabbit anticryptococcal antibody. A key feature of both reports was the need for antibody to be present at the time and site of challenge. In contrast, Louria and Kaminski found that passive immunization had no effect on survival time or the numbers of cryptococci in brain tissue if the mice were treated 24 h after challenge at a site that differed from the challenge route (15) . Without doubt, the most impressive results with passive immunization have been obtained by using MAbs specific for the capsular polysaccharide (3, 4) . Dromer et al. (3) found that a MAb of immunoglobulin G subclass 1 (IgGl) could extend the mean survival time of heavily infected DBA/2 mice from 3 days in untreated mice to 18 days for mice treated with MAb.
The biological activity of an immunoglobulin, and its potential efficacy in passive immunization, is influenced by * Corresponding author. the immunoglobulin subclass. For example, the subclasses of mouse IgG differ with regard to serum half-life (26) , ability to fix complement (19) , and ability to direct antibodydependent cell-mediated cytotoxicity (13) . In vivo studies have established the importance of antibody isotype in immunotherapy by using systems as diverse as (i) reduction in the number of schistosomula of Schistosoma mansoni in the lungs of infected rats (11) , (ii) inhibition of tumor growth in nude mice (25) , (iii) treatment of a murine B-cell lymphoma (12) , (iv) use of monoclonal anti-CD-4 antibodies to treat autoimmune disease mediated by T lymphocytes (27) , and (v) treatment of Escherichia coli Kl infection (20) .
In the accompanying paper, we describe the production and characterization of a subclass-switch family of MAbs reactive with an epitope shared by all four serotypes of cryptococcal polysaccharide (23 numbers of yeast cells in spleen and lung, passive immunization had no effect on the survival of mice challenged with Cryptococcus neoformans.
MATERIALS AND METHODS
MAbs and passive immunization. An isotype-switch family of MAbs was used for all experiments. The lineage of the complete family of isotype-switch variants was IgGl -> IgG2b -> IgG2a. Procedures for the production of the class-switch variants and the in vitro properties of the antibodies are described in an accompanying paper (23) . All antibodies were isolated from ascites fluid by immunoaffinity purification with a column in which cryptococcal polysaccharide had been coupled to AH-Sepharose (14) . The antibodies of each isotype were further purified on protein A-Sepharose to assure that there was no contamination by antibodies of other isotypes (23) .
Mice were injected intraperitoneally with MAbs of the IgGl, IgG2a, and IgG2b subclasses. Two treatment protocols were used. In a prophylaxis protocol, mice were given an injection of 1.0 mg of antibody 24 h prior to challenge with viable cryptococci. In the therapeutic protocol, mice were given 0.5 mg of antibody 48 h and again 96 h after infection with viable cryptococci. Control mice received a similar injection of sterile saline.
Murine cryptococcosis. C. neoformans 104 is an encapsulated serotype A isolate that was used in all studies. Cultures were maintained on slants of Sabouraud agar at room temperature. Seventy-two-hour cultures were used for challenge experiments. Yeast cell concentrations were determined by counting in a hemacytometer and confirmed by quantitative pour plates. Yeast viability was always greater than 85%. Female Swiss Webster mice, 6 to 10 weeks old (Charles River Breeding Laboratories, Inc., Wilmington, Mass.), were Survival after challenge with a lethal inoculum was used as an indicator of the effect of each MAb on the ultimate outcome of a cryptococcal infection. A comparison of mean survival time between groups of 12 mice indicated that no significant protection was conferred by any of the MAbs (Fig. 1 ). Mice that died had the weight loss and hydrocephalus characteristic of cryptococcal meningoencephalitis (4) . Table 2 . As with the prophylaxis protocol, a wide variation within all experimental groups contributed to large standard deviation. Treatment of infected mice with IgGl, IgG2a, or IgG2b had no effect on the number of yeast cells in brain tissue. In contrast to the lack of effect on brain tissue, the IgG2a and IgG2b antibodies significantly reduced the number of cryptococci in lung and spleen in both experiments. The IgGl antibody had no significant effect on the number of cryptococci in the lung but reduced the number of viable yeast cells in the spleen. The effect of IgGl on the spleen was significant in one of the two experiments.
The studies described above showed that the treatment of infected mice with antibodies of the IgG2a and IgG2b isotypes altered the course of experimental cryptococcosis in the lung and spleen. Despite this apparent efficacy, survival studies (Fig. 2) Experiment 1 Lung 49,000 14,000 48,000 30,000 (P = 0.47) 1,400 3,000 (P < 0.001) 6,400 6,900 (P < 0.001) Spleen 21,000 22,000 7,100 6,600 (P = 0.12) 1,100 2,700 (P = 0.03) 2,000 3,600 (P = 0.03) Brain 43,000 + 26,000 43,000 32,000 (P = 0.48) 27,000 7,500 (P = 0.11) 42,000 15,000 (P = 0.47) Experiment 2 Lung 2,300,000 1,500,000 1,800,000 2,400,000 (P = 0.37) 190,000 _ 280,000 (P = 0.004) 320,000 70,000 (P = 0.004) Spleen 100,000 78,000 14,000 9,800 (P = 0.01) 4,400 1,900 (P = 0.01) 7 ,600 3,200 (P = 0.006) Brain 600,000 320,000 650,000 610,000 (P = 0.44) 500,000 500,000 (P = 0.38) 710,000 540,000 (P = 0.37) Previous studies of the biological properties of subclassswitch antibodies have also noted discrepancies between in vitro assays and in vivo efficacy (16, 25) . For example, Mujoo et al. (16) found that IgGl antibodies would not direct complement-mediated lysis or antibody-directed cell-mediated cytotoxicity against neuroblastoma tumor cells, but the IgGl antibody suppressed the growth of the tumor cells in nude mice. Passive immunization with MAbs had little effect on the number of cryptococci in brain tissue regardless of the treatment protocol or the antibody subclass. A significant reduction was noted in one group of mice treated with IgG2b in a prophylaxis protocol. This was only a threefold reduction, and the effect was not observed in a duplicate experiment. Our inability to appreciably influence the number of cryptococci in brain tissue is similar to an observation by Perfect et al. (21) that rabbits with high levels of serum anticryptococcal antibody do not have an increased ability to clear cryptococci from cerebrospinal fluid. The inability of MAbs to influence the number of cryptococci in brain tissue was reported recently by Dromer et al. (4) .
There are several possible reasons for the failure of passively administered antibody to reduce the number of cryptococci in brain tissue. One explanation is that passively administered antibody may not cross the blood-brain barrier. This explanation is consistent with the observation of Goren that encapsulated cryptococci in the liver and spleen of mice with high levels of circulating anticapsular antibody are coated with antibody (9) . In contrast, cryptococci in the brain tissue of hyperimmunized mice were not coated with antibody, suggesting that serum antibody is unable to reach cryptococci in brain tissue. More recently, Gigliotti et al. (7) examined a rabbit model of S. pneumoniae meningitis and reported that there was poor penetration of serum IgG into cerebrospinal fluid, even under conditions of acute inflammation. Additional factors that may contribute to the failure of passive immunization may be the relative absence of phagocytic cells or low complement levels in central nervous system tissue.
Despite a significant effect of passive immunization on the number of cryptococci in the lung and spleen, none of the antibodies influenced survival time. Thus, there was a close parallel between the inability to reduce the number of cryptococci in brain tissue and the inability to prolong survival time. Results from the prophylaxis protocols emphasize the ability of cryptococci to avoid the opsonizing action of antibody in establishing a central nervous system infection. Further, once established, a central nervous system infection is refractory to the action of antibody.
Our inability to prolong the lives of infected mice differs from results reported originally by Dromer et al. (3) . Dromer et al. found that untreated mice had a mean survival time of 1.5 to 3 days, whereas mice treated with 100 ,ug of MAb had a mean survival time of 12 to 18 days. The critical difference between the two studies that undoubtedly accounts for the disparate results was the strain of mouse used in each study (4 The potential value of MAbs in the treatment of cryptococcosis is uncertain. Given the ability of the antibodies to reduce the fungal load in the lungs, it is possible that passive immunization might prove more effective in protection against an intranasal challenge. The inability of passive immunization to prolong life and to effect clearance of the yeast from the brains of Swiss Webster mice suggests that it may be more difficult to treat a central nervous system infection by passive immunization alone. However, our results also indicate that MAbs of the IgG2a and IgG2b isotypes will reduce the fungal burden in the lung and spleen. There is a possibility that passive immunization could be used in conjunction with more conventional antibiotic therapy to either increase the efficacy of a treatment protocol or reduce the levels of antibiotic needed for the treatment of cryptococcosis. The viability of this approach is suggested by an earlier study which reported that passive immunization with anticryptococcal antibody markedly improved the ability of amphotericin B to prolong the survival of mice with experimental cryptococcosis (8) . Future studies of passive immunization should examine the ability of antibodies of the IgG2a and IgG2b isotypes to act synergistically with more conventional antifungal therapy (3) .
Immunoglobulin isotype may be of importance in avoiding potential side effects of passive immunization. Cryptococcosis frequently produces high levels of antigenemia, particularly in patients with acquired immunodeficiency syndrome. Passive immunization has the potential for producing in vivo immune complexes or inducing widespread complement activation with serious complications. We have found that the IgG2b antibody has a markedly decreased ability to precipitate cryptococcal polysaccharide (23) . As a consequence, this antibody may be less active in producing large-latticed complexes in vivo. Other studies have shown that antibodies of the IgG2a isotype have a diminished capacity for complement activation (19) . Taken together, these studies indicate that immunoglobulin isotype is a significant factor in any strategy that might use passive immunization for the treatment of cryptococcosis.
